Long-term Protection Against Hepatitis B After Newborn Vaccination: 20-year Follow-up
Overview
Authors
Affiliations
Background: Hepatitis B vaccination in children born to hepatitis B surface antigen (HBsAg)-positive mothers considerably decreases the risk of vertical transmission. However, whether this protection against carriage of hepatitis B virus is maintained into early adulthood is as yet unknown.
Patients And Methods: A combined passive-active immunization programme for newborns of HBsAg-positive mothers was initiated in the north-eastern part of the Czech Republic in 1988. The number of immunized newborns had reached 665 newborns by the end of 2006. All mothers of immunized infants were HBsAg-positive during pregnancy, and 34 (5%) were also hepatitis B e antigen (HBeAg)-positive. The immunization programme consists of providing newborns with protection at birth with hepatitis B immunoglobulin, followed by three 10-μg doses of plasma-derived or, since 1990, recombinant vaccine administered at 0, 1 and 6 months of life. Only 29 children of HBeAg-positive mothers received vaccine at 0, 1 and 2 months of life. Blood samples were obtained after immunization, at 2 years of age, and biennially thereafter. Samples were tested for HBsAg and hepatitis B surface and core antibodies (anti-HBs, anti-HBc).
Results: The immunization schedules were completed in 640 children. A protective anti-HBs level after immunization was proven in 574 of 620 children (93%). Persistence of protective anti-HBs antibodies was detected in 70, 40 and 25% of children at 5, 10 and 15 years of age. Vertical transmission with chronic HBsAg carrier status was detected in two infants. Anti-HBc seroconversion was proven in ten children from 3 to 15 years of age. Natural boosting with an anti-HBs increase was detected in 38 children (twice in one child).
Conclusion: Our results show that combined active-passive immunization of newborns against hepatitis B provides persistent protection up to adolescence despite a frequent waning of anti-HBs antibodies, suggesting there is no need for booster vaccination during adolescence.
Gu J, Xu Y, Yuan J, Chen Y, Luo J, Guo C JMIR Public Health Surveill. 2024; 10:e60021.
PMID: 39230944 PMC: 11411227. DOI: 10.2196/60021.
Reduced protective efficacy of hepatitis B vaccine among fully vaccinated children in Ethiopia.
Adugna A, Demeke G, Toru M, Tsehay D, Esmael A, Mihret A PLoS One. 2023; 18(7):e0288355.
PMID: 37418447 PMC: 10328307. DOI: 10.1371/journal.pone.0288355.
Song Y, Zhang X, Liu M, Zhai X, Liu J, Li Y BMC Infect Dis. 2022; 22(1):863.
PMID: 36401190 PMC: 9673382. DOI: 10.1186/s12879-022-07854-w.
Nunez Cuadros E, Calzada-Hernandez J, Clemente D, Guillen Martin S, Silveira L, Lirola-Cruz M Eur J Pediatr. 2022; 181(6):2343-2354.
PMID: 35258699 PMC: 9110499. DOI: 10.1007/s00431-022-04418-7.
Phattraprayoon N, Kakheaw J, Soonklang K, Cheirsilpa K, Ungtrakul T, Auewarakul C Vaccines (Basel). 2022; 10(2).
PMID: 35214725 PMC: 8878162. DOI: 10.3390/vaccines10020267.